Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#2920 Mutation Spectrums Analysis of Colorectal Adenocarcinoma and Neuroendocrine Neoplasm Based on Same Genetic Background to Reveal Tumorigenesis

Introduction: The tumorigenesis of neuroendocrine neoplasm (NEN) are still ambiguous. The therapies of NENs in colon or rectum refer to adenocarcinomas (AC) when tumor metastasis, but the response was unsatisfactory which inspired us to explore the mutation difference.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hu H

Authors: Cai W, Ge W, Wu D, Mao J, Hu H,

Keywords: Neuroendocrine neoplasm, Tumorigenesis, Mutation spectrums, Colorectal,

#2200 Tumor Size Correlates with Grading in Nonfunctioning Pancreatic Neuroendocrine Tumors and Is Not Age-Dependent

Introduction: Tumor growth and Ki67 value increase are associated with aggressiveness in nonfunctioning pancreatic neuroendocrine tumours (NF-PanNET), but their natural history is largely unknown. It is unknown if the evolution of NF-PanNET is time-dependant.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Muffatti F

Authors: Muffatti F, Partelli S, Rancoita P, Andreasi V, Giannone F,

Keywords: NF-PanNET, tumor size, age, Ki-67,

#2106 Long-Acting Somatostatin Analogue (LA-SSA) Treatment Patterns in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden

Introduction: The main pharmacological treatment for metastatic GEP-NET G1/G2 is LA-SSA.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Berthon A

Authors: Berthon A, Björstad �, Granfeldt D, Marlow T, Dinét J,

Keywords: metastatic, GEP-NET, somatostatin analogues, treatment,

#2105 Long-Acting Somatostatin Analogue (LA-SSA) Treatment Durations in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden

Introduction: The main pharmacological treatment for metastatic GEP-NET G1/G2 is LA-SSA.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Berthon A

Authors: Berthon A, Granfeldt D, Björstad A, Marlow T, Dinét J,

Keywords: metastatic, GEP-NET, somatostatin analogues, treatment,

#2104 Direct Cost of Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Relation to Time Since Diagnosis Shows Growing Importance of Somatostatin Analogues (SSA)

Introduction: Metastatic GEP-NET G1/G2 incurs large costs on the Swedish health care system.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Berthon A

Authors: Berthon A, Granfeldt D, Björstad A, Marlow T, Dinét J,

Keywords: metastatic, GEP-NET, cost-of-illness, somatostatin analogues,